DiNardo CD, Marvin-Peek J, Loghavi S, Takahashi K, et al. Outcomes of Frontline Triplet Regimens With a Hypomethylating Agent, Venetoclax, and Isocitrate Dehydrogenase Inhibitor for Intensive Chemotherapy-Ineligible Patients With Isocitrate Dehydrogenase-Mutated AML. J Clin Oncol 2025;43:2692-2699.
PMID: 40513054